ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY

For patients with WHO grade II meningioma, the two-year and five-year overall survival is 93% and 73%, respectively. Patients with malignant meningioma (grade III) have significantly worse outcomes, with five-year overall survival rates of 42%. The recurrence rate remains high with overall survival...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Kumthekar, Priya, Kruser, Tim, Sachev, Sean, Raizer, Jeffrey, Grimm, Sean, Dixit, Karen
Format: Artigo
Language:Inglês
Published: Oxford University Press 2018
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216118/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.000
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items